DNA

#2377
Ginkgo Bioworks Holdings, Inc. Class A Common Stock
9.5 6 USD
+2.47%
Secteur: Soins de Santé
Base: USD
Devise de Profit: USD
Range quotidien
9.50
9.75
Range Annuel
5.37
10.64
Changement quotidien
+2.47%
Changement Mensuel
+27.21%
Evolution sur 6 mois
+7.66%
Changement Annuel
+7.66%
Clôture Précédente
9.3 3
Open
9.5 9
Low
9.5 0
High
9.7 5
Volume
204
Afficher le graphique complet Full chart

Financials

Aperçu Relevé Statistiques
Trimestriel Annuel
  • Market Capitalization 595.82 M
  • Employee 485
  • Founded 2008
  • CEO Jason Kelly
  • Website www.ginkgobioworks.com
  • Headquarter Delaware, United States
  • FIGI BBG00YPS1KY3
  • Industry Biotechnologies
Chiffre d'affaires total
Résultat net
Bénéfice par action de base (BPA de base)
Dette totale
Flux de trésorerie disponible
Trésorerie et équivalents de trésorerie
ratio cours/bénéfice
-1.47
ratio cours/chiffre d'affaires
2.71

Ginkgo Bioworks Holdings, Inc. Class A Common Stock

Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It raised $290 million in September and $350 million in October of that year. Ginkgo Bioworks went public on the New York Stock Exchange via a SPAC merger on September 17, 2021.

Nouvelles